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Abstract
Cardiovascular (CV) complications are the major cause of death in autosomal-dominant polycys-
tic kidney disease (ADPKD) patients. Hypertension is common in these patients even before the
onset of renal insufficiency. Blood pressure (BP) elevation is a key factor in patient outcome,
mainly owing to the high prevalence of target organ damage together with a poor renal progno-
sis when BP is increased. Many factors have been implicated in the pathogenesis of hypertension,
including the renin–angiotensin–aldosterone system (RAAS) stimulation. Polycystin deficiency
may also contribute to hypertension because of its potential role in regulating the vascular tone.
Early diagnosis and treatment of hypertension improve the CV and renal complications of this
population. Ambulatory BP monitoring is recommended for prompt diagnosis of hypertension. CV
risk assessment is mandatory. Even though a nonpharmacological approach should not be neg-
lected, RAAS inhibitors are the cornerstone of hypertension treatment. Calcium channel blockers
(CCBs) should be avoided unless resistant hypertension is present. The BP should be <140/90
mmHg in all ADPKD patients and a more intensive control (<135/85 mmHg) should be pursued as
soon as microalbuminuria or left ventricle hypertrophy is present.
Keywords: ambulatory blood pressure monitoring; blood pressure profile; cardiovascular risk; polycystic kidney disease;
renal size
Introduction
Autosomal-dominant polycystic kidney disease (ADPKD) is
the most common inherited renal disorder, affecting one
in 400–1000 live births. It accounts for ∼5–7% of cases of
end-stage renal disease (ESRD) requiring renal replace-
ment therapy in Europe and the USA [1]. It is character-
ized by the development of renal cysts. Although there is
considerable phenotypic variability, in general during the
first three decades only a few renal cysts are clinically de-
tectable, while by the fifth decade many renal cysts can
be found [2]. Progressive cyst expansion leads to massive
enlargement and distortion of the kidney’s architecture
and, ultimately, to ESRD in most patients [3].
ADPKD is genetically heterogeneous with two genes
causing the disease, PKD1 and PKD2 [4]. PKD1 accounts
for 85% of cases in clinically identified populations and
PKD2 accounts for the remaining 15% [5]. PKD1 causes
more severe disease, with a mean age at the onset of
ESRD of 53 years, compared with 69 years in cases due
to PKD2 [6]. Studies in animal models have shown that
ADPKD shows abnormal primary cilia function. The
primary cilium is a microtubule-based antenna-like struc-
ture rooted in the mother centriole (the basal body) that
projects from the surface of virtually all cells in the mam-
malian body. This cilium is a sensory organelle that re-
ceives mechanical and chemical signals from other cells
and the environment, and transmits these signals to the
nucleus to elicit a cellular response. Polycystins are the
ADPKD proteins; they form a complex that localizes to
primary cilia and may act as a mechanosensor essential
for maintaining the differentiated state of epithelia lining
tubules in the kidney and other tissues [7]. Therefore,
ADPKD is a systemic disease, with cyst development also
in the liver, pancreas, spleen, seminal vesicles, ovary and
arachnoid. Vasculature is also affected, and intra- and
extracranial aneurysms are more common in ADPKD
patients than in the general population. Cardiac and valv-
ular disorders have also been described [8]. These cardio-
vascular (CV) disorders contribute to the high CV
morbidity and mortality affecting ADPKD patients. In
addition, hypertension is a common symptom of ADPKD
that occurs in nearly 60% of patients before deterioration
of renal function [9]. Hypertension is associated with
rapid progression to ESRD and is also a major CV risk
factor [10]. The present article reviews the main charac-
teristics of hypertension in ADPKD patients, including
pathophysiological factors and treatment strategies.
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Arterial hypertension
Arterial hypertension is highly prevalent in ADPKD
patients compared with patients with other types of
renal disease. Nearly 60% of ADPKD patients have hyper-
tension before any decrease in the glomerular filtration
rate [9]. Hypertension occurs earlier and more frequently
in PKD1 than in PKD2 and in those ADPKD patients whose
affected or unaffected parents also have hypertension
[11]. ADPKD children also have a high prevalence of hy-
pertension [12] and data from large registries show that
ADPKD children show 4–6 mmHg higher blood pressure
than their age- and sex-matched controls and more fre-
quently a non-dipper profile in the ambulatory blood
pressure (BP) monitoring [13] Indeed, this prevalence
may be even higher if ambulatory BP monitoring is used
to make the diagnosis, owing to the high proportion of
masked hypertension in this population [14]. BP monitor-
ing helps us to make an early diagnosis of hypertension
and to identify non-dipping circadian BP rhythm (<10%
decline in nocturnal systolic or diastolic BP), which is
common (∼45%) in ADPKD patients [15]. The CV risk
associated with hypertension has two components, the
BP elevation and the BP circadian rhythm alteration.
Many studies have demonstrated that blunted nocturnal
dip is associated with high CV risk and that reversal of
the non-dipping status improves the CV prognosis [16,
17]. In addition, ambulatory BP monitoring has been de-
monstrated to improve the diagnosis of hypertension,
avoiding the under- and overestimation associated with
BP control at the office [18]. Nowadays, clinical guidelines
on hypertension worldwide recommend the use of ambu-
latory BP monitoring to diagnose and follow up hyperten-
sive patients [19].
Hypertensive ADPKD patients also have a greater
incidence of target organ damage compared with
other age-matched hypertensive patients. Nearly 50% of
hypertensive ADPKD patients exhibit left ventricular hy-
pertrophy on echocardiography [20]. Early diastolic dys-
function, including biventricular diastolic dysfunction, and
impaired coronary flow velocity reserve have also been
demonstrated [21]. These cardiac alterations have been
associated with hemodynamic factors including systolic
BP and lower nocturnal fall in BP rhythm [22]. However,
normotensive ADPKD patients also exhibit ventricular hy-
pertrophy (23%), which has not been associated with
blunted nocturnal fall in BP [23]. It appears that further
factors may be involved in left ventricular hypertrophy in
these patients. Recently, the HALT PKD study has shown
a lower incidence of left ventricular hypertrophy using
cardiac magnetic resonance [24].This low prevalence has
been attributed to the high use of angiotensin-converting
enzyme (ACE) inhibitors or angiotensin receptor blockers
(ARBs).
Urinary albumin excretion rate and glomerular filtration
rate are reliable markers for hypertension-related renal
damage. Moreover, albuminuria has a prognostic CV
value [25, 26]. In ADPKD patients, a higher albuminuria
level is associated with increased mean BP and more
severe renal cystic involvement [27]. Glomerular filtration,
however, appears to be stable in ADPKD for a long period,
despite progression of renal structural abnormalities due
to compensatory hyperfiltration [28]. Therefore, unlike in
other nephropathies, the glomerular filtration rate is not
a reliable marker of disease severity. Recently, the total
renal volume has been proposed as a marker for disease
severity and progression [29–31]. Indeed, the renal
volume can stratify ADPKD patients into high and low
risks for disease progression, the poorest prognosis exist-
ing among those with the greatest renal volume [32].
ADPKD patients present early pathology in the arterial
system. Young normotensive ADPKD patients have an im-
paired endothelium-dependent relaxation in small resist-
ance vessels and an amplification of the pulse wave that
may contribute to a higher left ventricular afterload [33].
At this early stage, radial or aortic pulse wave velocities
are within the normal range. In hypertensive ADPKD
patients, however, there is an increase in intima-media
thickness of the carotid arteries as well as a greater
prevalence of fibromatous areas in the carotid wall [34].
Later in the course of the disease, when renal insuffi-
ciency appears, there are important alterations in the
large arteries.
There are other important clinical data related to hy-
pertension in this population. First of all, there is an
association between hypertension and the increase in
kidney volume compared with normotensive ADPKD
patients [12, 35]. The exact mechanism of this associ-
ation is not completely clear although stimulation of the
RAAS could play an important role (see ‘Pathogenesis of
hypertension’). Second, there is an association between
hypertension and the decrease in kidney function. Many
studies have shown that hypertension is an independent
prognostic factor for progression to ESRD [10]. Typically,
ADPKD kidney histology from patients with ESRD presents
significant BP damage manifested by sclerosis of renal ar-
terioles and global glomerulosclerosis, a marker of renal
ischaemia [36].
Taken together, these data show significant target
organ damage in both normotensive and hypertensive
ADPKD patients which may explain in part the high CV
morbidity and mortality in these patients. A reduction in
CV mortality has been demonstrated, however, in the
past decade. This reduction has been attributed to early
diagnosis and treatment of ADPKD complications,
especially hypertension [37]. In this regard, early BP
treatment has decreased the prevalence of left ventricu-
lar hypertrophy in ADPKD patients [24].
Therefore, CV risk assessment should be applied to
ADPKD patients. This includes measurement of target
organ damage (Table 1), evaluation of classic CV risk
factors apart from hypertension (smoking habits, body
weight, lipid variables, etc.), and diagnostic studies of dia-
betes and other CV clinical conditions (cerebrovascular
disease, heart disease, peripheral artery disease, etc.)
Table 1. Subclinical organ damagea
(i) Electrocardiographic LVH (Sokolow–Lyon >38 mm; Cornell
>2440 mm×ms) or echocardiographic LVH (LVMI M > 125 g/m2,
F > 110 g/m2)
(ii) Carotid intima-medial thickening >0.9 mm or plaque
(iii) Carotid-femoral pulse wave velocity >12 m/s
(iv) Ankle/brachial BP index <0.9
(v) Slight increase in plasma creatinine: M: 115–133 mmol/L (1.3–1.5
mg/dL); F: 107–124 mmol/L (1.2–1.4 mg/dL)
(vi) Low eGFRb (<60 mL/min/1.73 m2) or creatinine clearancec
(<60 mL/min)
(vii) Albuminuria 30–300 mg/24 h or albumin–creatinine ratio: ≥22 (M) or
≥31 (F) mg/g creatinine
aM, males; F, females; BP, blood pressure; LVH, left ventricular
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[25]. In patients with important CV risk factors, like
ADPKD, early interventions should be implemented to
improve their risk profile. The main features of ADPKD hy-
pertension are summarized in Table 2.
Pathogenesis of hypertension
Activation of the RAAS seems to have a major role in the
pathogenesis of hypertension in ADPKD patients. Plasma
renin activity and plasma aldosterone concentration are
increased in ADPKD patients compared with essential hy-
pertensive patients matched for age, sex, kidney function,
sodium intake and degree of hypertension [38]. Along
with this systemic stimulation of the RAAS, local stimu-
lation has also been demonstrated. ADPKD kidneys show
hyperplasia of the juxtaglomerular apparatus [39]. In
addition, radiolabelling of renin and messenger RNA for
renin has been detected in the cyst wall epithelium to-
gether with high renin activity in the cyst fluid [40]. It has
been postulated that renal cysts enlarge and compress
the renal vasculature, favouring intrarenal ischaemia and
stimulation of the RAAS. Angiotensin II has an important
haemodynamic effect, but it is known that it may act as
a growth factor enhancing renal cyst growth and contri-
buting to this vicious circle. These data suggest that inhi-
bition of the RAAS may be important in controlling the BP
level, reducing the rate of cyst growth and renal enlarge-
ment, and finally slowing down the progression to ESRD.
Other pathogenic factors might also be involved in hy-
pertension. Intrarenal ischaemia/hypoxia is a potent
stimulator of erythropoietin concentration, which is in-
creased in patients with ADPKD [41]. Intrarenal ischae-
mia also affects renal tubular sodium handling and
increases the activity of the sympathetic nervous system,
which is known to be overstimulated in ADPKD patients
prior to any decrease in the glomerular filtration rate [42,
43]. Concentration ability is altered in hypertensive
ADPKD patients, possibly owing to increased circulating
vasopressin levels. This vasopressin elevation may also
contribute to the development of hypertension [44].
Vasoconstrictor factors appear to be increased in
ADPKD patients. Endothelin 1 is expressed in the kidney
cyst epithelium, in the cyst fluid, and also in plasma at a
higher concentration compared with normotensive and
hypertensive patients. On the other hand, endothelial
nitric oxide synthase activity is diminished, facilitating
the impaired endothelium-dependent relaxation ob-
served in ADPKD patients. Therefore, these patients
appear to have an imbalance between vasoconstrictor
and vasodilatation factors that may contribute to hyper-
tension [8]. Renal tissue nitric oxide synthase activity is
also reduced, which may activate local oxidative stress
pathways contributing to the renal damage [45].
Recently, it has been demonstrated that decreased
polycystin 1 or 2 expression in the cilia of endothelial
cells and in vascular smooth muscle cells is associated
with abnormal vascular structure and function. Polycystin
1 and 2 function is required for endothelial cilia to sense
fluid shear stress through a complex biochemical
cascade involving many factors, including nitric oxide.
Indeed, Pkd1/Pkd2 deficiency reduces nitric oxide levels
and alters the endothelial response to shear stress [13].
Polycystin deficiency interferes with the vascular tone
and may explain why hypertension is a primary feature in
ADPKD patients. This is a new pathogenic factor that
needs further investigation. Apart from the prevalence of
hypertension, it is not known whether the CV profile is
different between PKD1 and PKD2 patients. The main
pathogenic factors of ADPKD hypertension and CV risk
are summarized in Table 3.
Treatment of hypertension
Early and effective treatment of hypertension is very
important in ADPKD in order to slow down the pro-
gression to ESRD and prevent CV complications. Even
though many questions remain unanswered, there are
certain points in its treatment that should be taken into
account.
Lifestyle changes
Lifestyle changes should not be forgotten in these hyper-
tensive patients. Maintenance of ideal body weight,
regular aerobic exercise and a diet limited to a maximum
intake of 6 g of salt daily are suitable recommendations,
even though they have not been explicitly studied in
patients with ADPKD [2].
Vasopressin is a potent activator of renal cyclic adeno-
sine monophosphate (cAMP), which increases the pro-
liferation of epithelial cells in cyst walls and the rate of
fluid secretion into cysts and thus leads to kidney enlar-
gement, which has been shown to be the better predictor
of kidney disease progression in ADPKD [29]. The useful-
ness of vasopressin inhibitors in slowing down the pro-
gression of renal enlargement and deterioration of
estimated glomerular filtration rate (eGFR) in patients
with ADPKD has been demonstrated in a placebo-con-
trolled trial (TEMPO study) [46]. It has also been
suggested that a high fluid intake would behave similarly
to V2 receptor blocking [47, 48]. Based on the TEMPO trial
results and, especially, on the outcome of the control
group, which was advised to drink a lot of fluids, it seems
reasonable to recommend a water intake of ∼3000 mL
Table 2. Main features of hypertension in ADPKDa
(i) Associated with activation of the RAAS
(ii) Imbalance between vasoconstriction and vasodilatation factors
(iii) Appears early in the course of the disease, before a decrease in
renal function
(iv) High prevalence of non-dipping circadian rhythm
(v) High prevalence of target organ damage (ventricular hypertrophy,
increased carotid intima-media thickness, etc.)
(vi) Closely related to the kidney volume
(vii) Important prognostic factor for progression to ESRD
aRAAS, renin–angiotensin–aldosterone system; ESRD, end-stage renal
disease.
Table 3. Potential pathophysiological mechanisms of hypertension and
cardiovascular risk in early ADPKD
(i) Cyst growth and renal enlargement
(ii) Renal ischaemia/hypoxia
(iii) Increased in erythropoietin
(iv) Activation RAAS
(v) Increased in vasopressin and cAMP
(vi) Vascular dysfunction
(vii) Decreased nitric oxide production
(viii) Cardiac and valvular disorders
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per day to reduce AVP levels. This recommendation
should be given with caution because it can lead to hypo-
natraemia [2, 49].
Pharmacological treatment
The role of the different antihypertensive drugs in
relation to renal and CV outcomes will be analysed in this
section.
RAAS inhibitors. Activation of the RAAS seems to be the
cornerstone of the pathophysiology of hypertension in
ADPKD; therefore, most studies have investigated the re-
noprotective and CV effects of RAAS inhibitors compared
with other antihypertensive treatments. In this regard,
ACE inhibitors, e.g. enalapril and ramipril, and ARBs, e.g.
candesartan, have shown, compared with dihydropyri-
dine calcium channel blockers (CCBs), better antialbumi-
nuric effect and lower reduction in creatinine clearance
independent of BP levels [50, 51] and also greater
reduction of left ventricular hypertrophy [52]. Compared
with RAAS inhibitors, however, beta-blockers (atenolol
and metoprolol) have not shown worse results in terms
of eGFR, urinary albumin excretion or left ventricular hy-
pertrophy (even though the inhibition of the RAAS
caused by beta-blockers might have obscured the poten-
tial beneficial effects of ACE inhibitors) [53, 54]. On the
other hand, compared with ACE inhibitors, diuretic treat-
ment has shown a significantly greater decline in renal
function despite similar BP control, suggesting a role of
the RAAS independent of BP levels in the progression of
chronic kidney disease in ADPKD patients [55]. It must be
noted, however, that diuretics cause activation of the
RAAS, which may have interfered with these results. In
addition, diuretics may cause a certain volume depletion
which can also induce vasopressin release and an in-
crease in cAMP. It is known that ACE inhibitors and ARBs
alone fail to completely suppress the RAAS; the useful-
ness of the combination of these two classes of the drug
will be checked in the HALT trial, where ADPKD patients
in different stages of chronic kidney disease have been
randomized to receive ACE inhibitors plus angiotensin re-
ceptor blocking agents or ACE inhibitors versus ARB alone
[56] The role of the direct renin inhibitor aliskiren in
ADPKD patients is not yet known; however, it could be rel-
evant given that this is the only RAAS inhibitor which also
suppresses plasma renin activity [57, 58].
To our knowledge, no study has yet compared the
renal or cardiovascular outcomes between ADPKD
patients treated with ACE inhibitors and those treated
with ARBs alone. Nor is there any evidence available on
potential beneficial effects of adding spironolactone to
ACE inhibitors or to ARBs.
Calcium channel blockers. cAMP accelerates the prolifer-
ation of cyst-derived cells in ADPKD, but does not activate
proliferation of normal renal cells. This phenotypic differ-
ence in the proliferative response to cAMP appears to be
secondary to differences in basal intracellular calcium
levels, which have been shown to be reduced in epithelial
cells isolated from human ADPKD cysts compared with
normal renal cells [59]. The CCB verapamil had no effect
on kidney morphology in wild-type rats while ADPKD rats
showed greater kidney weight and cyst index and in-
creased cell proliferation and apoptosis, with consequent
exacerbation of renal cystic disease [60]. In humans, di-
hydropyridine CCBs have been compared with RAAS
inhibitors (ACE inhibitors and ARBs), and patients receiv-
ing CCB treatment appeared to have a poorer renal func-
tion outcome [61]. Because of these findings, both
dihydropyridine and non-dihydropyridine CCBs should
probably be avoided as first- and probably second-line
treatment in patients with ADPKD. However, considering
that ADPKD patients often show resistant hypertension
and CCBs are good antihypertensive drugs, they should
certainly be third-line treatment.
Diuretics. Because aldosterone levels are greater in hy-
pertensive ADPKD patients than in essential hyperten-
sives, and higher aldosterone levels may lead to sodium
retention, diuretics should be considered as second-line
treatment in hypertensive ADPKD. It must be noted,
however, that diuretic treatment may lead to an extra
activation of the RAAS owing to volume depletion. In hy-
pertensive ADPKD patients with normal renal function,
thiazide diuretics are the first choice. In those with im-
paired renal function and glomerular filtration rate <30
mL/min/1.73 m2, long-acting loop diuretics must be the
first choice.
To our knowledge, other drug treatments (e.g. alpha-
blockers, direct vasodilators) have not been compared
with RAAS inhibitors and may play a secondary role in hy-
pertension treatment in this population.
Blood pressure goal
Another important point to be considered is the BP goal.
The Modified Diet in Renal Disease study, which included
200 participants with ADPKD, compared two levels of BP
control in patients with a glomerular filtration rate
between 13 and 55 mL/min/1.73 m2. No benefits were
found in the lower BP control (mean BP <92 versus <107
mmHg) group in terms of renal function decline,
although the fact that patients already had substantial
renal impairment may have masked the results [62].
However, it has been demonstrated that intensive BP
control (BP 120–125/80 mmHg) results in a reduction in
urinary albumin excretion and left ventricular hypertro-
phy (both indirect markers of cardiovascular and renal
prognosis), suggesting that this intensive BP target might
offer major benefits [54]. Again, the results of the HALT
trial, expected by 2013, may give an answer on the real
beneficial effects of intensive (BP <95–110/60–75 mmHg)
versus standard (BP <120–130/70–80 mmHg) BP control
in early stages of ADPKD (eGFR >60 mL/min/1.73 m2).
In summary, until more evidence is available, hyper-
tensive ADPKD patients should have a BP of <140/90
mmHg. Even though, as stated in the ‘Reappraisal of
guidelines on hypertension management’ of the European
Society of Hypertension in relation to essential hyperten-
sion and knowing that ADPKD patients show greater
target organ damage than their essential hypertensive
controls, it might be recommended to try to reach BP
levels closer to 130–135/80–85 mmHg in those with
target organ damage already present [63]; this is a
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recommendation not based on evidence, as to date there
have been no studies giving a clear answer to this.
Summary
CV complications are the major cause of death in ADPKD
patients. Hypertension is common in these patients even
before the onset of renal insufficiency. BP elevation is a
key factor in patient outcome, mainly owing to the high
prevalence of target organ damage together with a poor
renal prognosis when BP is increased. Many factors have
been implicated in the pathogenesis of hypertension, in-
cluding RAAS stimulation. Polycystin deficiency may also
contribute to hypertension because of its potential role in
regulating the vascular tone. Early diagnosis and treat-
ment of hypertension improve the CV and renal compli-
cations of this population. Ambulatory BP monitoring is
recommended for prompt diagnosis of hypertension. CV
risk assessment is mandatory. Even though a nonphar-
macological approach should not be neglected, RAAS
inhibitors are the cornerstone of hypertension treatment.
CCBs should be avoided unless resistant hypertension is
present. The BP should be <140/90 mmHg in all ADPKD
patients and a more intensive control (<135/85 mmHg)
should be pursued as soon as microalbuminuria or left
ventricle hypertrophy is present [64]. Pharmacological re-
gimens must include an RAAS inhibitor as first option and
probably a beta-blocker as a second option, leaving CCBs
for those with resistant hypertension and diuretics for
those with impaired renal function and water overload.
Other modifiable CV risk factors must be promptly
treated; statins should be started if LDL cholesterol levels
are >130 mg/dL (3.37 mmol/L) and smoking cessation
must be encouraged (Figure 1).
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